Nels P Nielson

This inventor holds 13 USPTO granted patents and 14 published patent applications and 3 EPO patents. Top assignees: Potenza Therapeutics, Inc., Five Prime Therapeutics, Inc., Surface Oncology, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nels P Nielson. Retrieved from https://idiyas.com/inventor/nels-p-nielson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 14)

% Patents Active = 69.2

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 6.6

ph-index = 3

Forward Citations = 39(Granted Patents)

Location History:

Cambridge, MA (US) (2022)
Lebanon, NH (US) (2017 - 2023)

Company Filing History:

7 out of 7

Potenza Therapeutics, Inc.

patents

3 out of 77

Five Prime Therapeutics, Inc.

patents

3 out of 13

Surface Oncology, Inc.

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679892 - B7-H4 ANTIBODIES AND METHODS OF USE THEREOF (2026-07-14),

2. 11814431 - B7-H4 antibodies and methods of use thereof (2023-11-14),

3. 11655303 - Anti-CD39 antibody compositions and methods (2023-05-23),

4. 11590224 - Anti-TIGIT antigen-binding proteins and methods of uses thereof (2023-02-28),

5. 11453720 - Anti-TIGIT antigen-binding proteins and methods of use thereof (2022-09-27),

6. 11306144 - B7-H4 antibodies and methods of use thereof (2022-04-19),

7. 11186644 - Anti-neuropilin antigen-binding proteins and methods of use thereof (2021-11-30),

8. 10988545 - Anti-GITR antigen-binding proteins and methods of use thereof (2021-04-27),

9. 10793637 - Antibodies that bind CD39 and uses thereof (2020-10-06),

10. 10738128 - Antibodies that bind CD39 and uses thereof (2020-08-11),

11. 10507244 - Anti-TIGIT antigen-binding proteins and methods of use thereof (2019-12-17),

12. 10227413 - Anti-neuropilin antigen-binding proteins and methods of use thereof (2019-03-12),

13. 9713641 - Anti-TIGIT antigen-binding proteins and methods of use thereof (2017-07-25),

Title: Nels P Nielson: Innovator in Antibody Therapeutics

Introduction

Nels P Nielson is a prominent inventor based in Lebanon, NH (US), known for his significant contributions to the field of antibody therapeutics. With a total of 13 patents, Nielson has made remarkable strides in developing innovative solutions for treating various disorders, particularly cancer.

Latest Patents

Among his latest patents is the development of B7-H4 antibodies and methods of use thereof. This patent provides antibodies and antigen-binding fragments that specifically bind to human B7-H4, with potential applications in increasing T cell proliferation and treating disorders such as cancer. Another notable patent involves anti-CD39 antibody compositions, which are designed for use in cancer treatment. These inventions highlight Nielson's commitment to advancing medical science through innovative antibody therapies.

Career Highlights

Throughout his career, Nels P Nielson has worked with several notable companies, including Potenza Therapeutics, Inc. and Surface Oncology, Inc. His work in these organizations has contributed to the development of cutting-edge therapies that address critical health challenges.

Collaborations

Nielson has collaborated with esteemed colleagues such as Daniel Hicklin and William Winston, further enhancing the impact of his work in the field of antibody research.

Conclusion

Nels P Nielson's innovative contributions to antibody therapeutics have positioned him as a key figure in the fight against cancer. His patents and collaborations reflect a dedication to improving patient outcomes through scientific advancement.

Profile summary based on public USPTO records.